In addition, a study in ovarian carcinomas showed that ARID1A deficiency – via interaction with MutS protein homolog 2 (MSH2) – leads to an impaired MMR phenotype in tumour cells that could be used for immunotherapy [23]. Here, ARID1A is linked to neoplasm.